Drug Trial Radar · NCT07038382
A Study to Evaluate the Efficacy, Safety, and Tolerability of Human Sialidase Fusion Protein (HLX79) in Combination With Rituximab Injection Versus Placebo in Patients With Active Glomerulonephritis
Last checked: Nov 19, 2026Latest source record: Nov 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
24
Planned (sponsor's estimate)
Start
Aug 5, 2025
Primary completion
Jan 2027
Study completion May 2030
Sponsor
- Lead sponsor
- Shanghai Henlius BiotechIndustry
- Sponsor type
- Industry
- First posted
- Jun 26, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objectives of this clinical trial is to evaluate the safety and tolerability of HLX79 in combination with HLX01 versus placebo in combination with HLX01 in the treatment of glomerulonephritis. The secondary objective are to evaluate the pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of HLX79 and HLX01, the clinical efficacy, the dynamic changes of biomarkers of HLX79 in combination with HLX01 in the treatment of glomerulonephritis. The subjects will receive different doses of HLX79 (10, 20, or 30 mg/kg) or placebo, all in combination with HLX01. After the end of the first treatment period, subjects will enter a 20-week follow-up period and then undergo pre-second treatment period assessments. If the investigator determines that the subject does not require the second treatment period, the subject will continue in follow-up until completing the total 48-week follow-up period.
Conditions
- Membranous Nephropathy
- Lupus Nephritis (LN)
Interventions
HLX79 10mg/kg/Placebo+HLX01Drug
Subjects with MN will receive HLX79 10mg/kg or placebo, combine with HLX01 375 mg/m2
HLX79 20mg/kg/Placebo + HLX01Drug
Subjects with MN will receive HLX79 20mg/kg or placebo combined with HLX01 375 mg/m2
HLX79 30mg/kg/placebo+HLX01Drug
Subjects with MN will receive HLX79 30mg/kg or placebo combined with HLX01 375 mg/m2
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to TreatmentTime frame: 24 weeks
Locations
17 sites in 1 country. Site status is shown where the registry gives one.
Beijing Tsinghua Changgung Hospital
Beijing, China · Not yet recruiting
Peking University People's Hospital
Beijing, China · Not yet recruiting
Xiangya Hospital Of Gentral South University
Changsha, China · Not yet recruiting
Guangdong Provincial People's Hospital
Guangzhou, China · Not yet recruiting
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Guangzhou, China · Not yet recruiting
The First Affiliated Hospital Zhejiang University School Of Medicine
Hangzhou, China · Not yet recruiting
The Second Hospital of Anhui Medical University
Hefei, China · Not yet recruiting
The First Affiliated Hospital of Henan University of Science and Technology
Luoyang, China · Not yet recruiting
Jiangxi Provincial People's Hospital
Nanchang, China · Not yet recruiting
The First Affiliated Hospital of Nanchang University
Nanchang, China · Not yet recruiting
Jiangsu Province Hospital
Nanjing, China · Not yet recruiting
Zhongdong Hospital Southeast University
Nanjing, China · Not yet recruiting
Shanghai General Hospital
Shanghai, China · Recruiting
Renmin Hospital Of Wuhan University
Wuhan, China · Not yet recruiting
The First Affiliated Hospital of Xi'an Jiao Tong University
Xi'an, China · Not yet recruiting
The First Affiliated Hospital Of Xiamen University
Xiamen, China · Not yet recruiting
Su Bei People's Hospital
Yangzhou, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.